Literature DB >> 16940033

Inconsistencies between cytokine profiles, antibody responses, and respiratory hyperresponsiveness following dermal exposure to isocyanates.

Maryjanek Selgrade1, Elizabeth H Boykin, Najwa Haykal-Coates, Michael R Woolhiser, Connie Wiescinski, Debora L Andrews, Aimen K Farraj, Donald L Doerfler, Stephen H Gavett.   

Abstract

Cytokine profiling of local lymph node responses has been proposed as a simple test to identify chemicals, such as low molecular weight diisocyanates, that pose a significant risk of occupational asthma. Previously, we reported cytokine messenger RNA (mRNA) profiles for dinitrochlorobenzene (DNCB) and six isocyanates: toluene diisocyanate, diphenylmethane-4,4'-diisocyanate, dicyclohexylmethane-4,4'-diisocyanate, isophorone diisocyanate, p-tolyl(mono)isocyanate, and meta-tetramethylene xylene diisocyanate. The present study was conducted to test the hypothesis that relative differences in the cytokine profile are predictive of relative differences in total serum immunoglobulin (Ig) E and respiratory responses to methacholine (Mch) following dermal exposure to the chemicals. After a preliminary experiment to determine an exposure regimen sufficient to achieve responses to Mch following dermal diisocyanate exposure, BALB/c mice received nine dermal exposures over a period of 28 days to one of six isocyanates, DNCB, or vehicle. Mice were then challenged with increasing doses of Mch and responsiveness was assessed using whole-body plethysmography. Serum antibody responses and cytokine mRNA profiles in the draining lymph node were also assessed. In separate experiments, cytokine protein assays were performed after five dermal exposures over a 14-day period. The response pattern for interleukin (IL)-4, IL-10, and IL-13 for the different isocyanates was highly reproducible as determined by RNAse protection assay, reverse transcription-PCR, or cytokine protein levels. However, the relative differences in T-helper cytokine profiles were not predictive of relative differences in either total serum IgE or respiratory responses to Mch following dermal exposure. The data suggest that the cytokine profiling approach needs to be further developed and refined before adoption and that other approaches to hazard identification should be pursued as well. Based on the weight of evidence from all the assays performed, it appears that all six isocyanates tested have some potential to cause respiratory hypersensitivity following dermal exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940033     DOI: 10.1093/toxsci/kfl094

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  6 in total

Review 1.  Developments in laboratory diagnostics for isocyanate asthma.

Authors:  Adam V Wisnewski
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-04

Review 2.  Methyl methacrylate and respiratory sensitization: a critical review.

Authors:  Jonathan Borak; Cheryl Fields; Larry S Andrews; Mark A Pemberton
Journal:  Crit Rev Toxicol       Date:  2011-03       Impact factor: 5.635

3.  Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response.

Authors:  M-L Wong; C Dong; J Maestre-Mesa; J Licinio
Journal:  Mol Psychiatry       Date:  2008-05-27       Impact factor: 15.992

4.  Physiological responses to cisplatin using a mouse hypersensitivity model.

Authors:  David M Lehmann; Wanda C Williams
Journal:  Inhal Toxicol       Date:  2020-03-18       Impact factor: 2.724

5.  Immune sensitization to methylene diphenyl diisocyanate (MDI) resulting from skin exposure: albumin as a carrier protein connecting skin exposure to subsequent respiratory responses.

Authors:  Adam V Wisnewski; Lan Xu; Eve Robinson; Jian Liu; Carrie A Redlich; Christina A Herrick
Journal:  J Occup Med Toxicol       Date:  2011-03-17       Impact factor: 2.646

6.  Risk Assessment for Toluene Diisocyanate and Respiratory Disease Human Studies.

Authors:  Robert M Park
Journal:  Saf Health Work       Date:  2020-12-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.